Showing 2991-3000 of 3017 results for "".
Updates from ASDS and ISHRS
https://practicaldermatology.com/series/dermwire-tv/-dermwiretv-updates-from-asds-and-ishrs/18217/The Annual meeting of the American Society for Dermatologic Surgery (ASDS) gathered experts in dermatologic surgery in Phoenix. Joel L. Cohen, MD and Shannon Humphrey, MD, who received the 2018 ASDS Award for Outstanding Service, discussed effective cosmetic consults. Diane Berson, MD addressed botheRelevance Uncovers Marketing Truths, EADV Data, Primetime for Botox
https://practicaldermatology.com/series/dermwire-tv/erelevance-uncovers-marketing-truths-eadv-data-primetime-for-botox/18429/The State of Aesthetic Healthcare Marketing 2017 from eRelevance shows that nearly 60 percent of aesthetic physicians say they either don't see results from their marketing initiatives or aren't able to measure results. Data presented at the annual meeting of the European Academy of Dermatology andRisk In Your Portfolio
https://practicaldermatology.com/topics/practice-management/risk-in-your-portfolio/18588/Do you know your risk score? Physicians must understand their personal tolerance for risk as well as the level of risk in their current portfolios. If there is a mismatch, how do you rectify the disconnect. Bob Peelman, CFP, of OJM Group, explains. ABOUT THE AUTHORAsk An Expert: Establishing Yourself as an Expert
https://practicaldermatology.com/topics/practice-management/ask-an-expert-establishing-yourself-as-an-expert/18937/In this edition of NewDermMD's video series, host Adam Friedman, MD speaks with Neal Bhatia, MD about establishing one's expertise, becoming an educator, and finding a comfortable place working with industry, peers, and societies. Whether your interest is in cosmetic dermatology, acne, psoriasis, peHolding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-frontline-treatment-approach-for-stage-iv-braf-wild-type-melanoma/15436/How can we make an informed decision on which target combined with a PD-1 inhibitor provides the most benefit in patients with metastatic melanoma?Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/Are you as excited as our experts are about immunotherapy for the adjuvant treatment of stage IIB/IIC melanoma? Tune in to find out why you should be!AD Impact, Allofill Comes to Market, GPA Launches
https://practicaldermatology.com/topics/psoriasis/dermwiretv-ad-impact-allofill-comes-to-market-gpa-launches/18567/From sleep disruptions or negative impact on the ability to work to feelings of depression and anxiety, atopic dermatitis can have significant effects on adults, new research suggests. In fact, more than half of respondents to a Harris Poll say that AD has negatively impacted their daily lives. DoriPruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
https://practicaldermatology.com/programs/cme/pruritus-cases-from-the-field-real-world-perspectives-on-managing-ckd-ap/14969/Did you know that many patients on dialysis suffer from itch, or pruritus? Hear patients describe their experiences with a new FDA-approved therapy.Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
https://practicaldermatology.com/programs/cme/directed-relief-in-ckd-ap-linking-targeted-therapy-to-clinical-outcomes/14967/Join our experts’ discussion to learn how to significantly improve quality of life for your patients with chronic kidney disease-associated pruritus.The Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and c